Lexicon Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 02, 2022 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
Sotagliflozin New Drug Application for Heart Failure Accepted for Review by FDA,with PDUFA Action Date Anticipated in May 2023 LX9211 Phase 2 Clinical Proof-of-Concept Achieved in Painful Diabetic...
Lexicon Pharmaceuticals to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 2, 2022
July 29, 2022 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 29, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2022 financial results on Tuesday, August 2, 2022 after the...
Lexicon Announces Pricing of $85.0 Million Public Offering and Concurrent Private Placement
July 28, 2022 07:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering...
Lexicon Announces Proposed Public Offering Of Common Stock
July 27, 2022 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and...
Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
July 27, 2022 07:59 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and...
Lexicon Announces Positive Top-Line Results From Phase 2 Proof-Of-Concept Study Of LX9211 In Painful Diabetic Neuropathy
June 29, 2022 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
Study Supports Translation of Potential New Mechanism of Action for Neuropathic Pain and Advancement of LX9211 Development in Painful Diabetic Neuropathy Conference Call and Webcast at 8:00 a.m....
Lexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare Conference
June 01, 2022 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, June 01, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the...
Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
May 31, 2022 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, May 31, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug...
Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update
May 05, 2022 06:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2022 and provided an update...
Lexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022
April 29, 2022 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2022 financial results on Thursday, May 5, 2022 before the...